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fistula failure
Emma Aitken1*, Andrew Jackson1,2, Chia Kong3, Paul Coats2 and David Kingsmore1Abstract
Background: Guidance varies regarding the optimal timing of arteriovenous fistula (AVF) creation. The aim of this
study was to evaluate the association between uraemia, haemodialysis and early AVF failure.
Methods: Immunoblotting and cell proliferation assays were performed on vascular smooth muscle cells (VSM)
cells isolated from long saphenous vein samples to evaluate the cells’ ability to proliferate when stimulated with
uraemic (post-dialysis) and hyperuraemic (pre-dialysis) serum. Clinical data was collected prospectively for 569
consecutive radiocephalic (RCF) and brachiocephalic (BCF) fistulae. The primary outcome was AVF failure at
6 weeks. Dialysis status (haemodialysis (HD); pre-dialysis (Pre-D)), eGFR and serum urea were evaluated to determine
if they affected early AVF failure.
Results: Human VSM cells demonstrated increased capacity to proliferate when stimulated with hyperuraemic
serum. There was no significant difference in early failure rate of either RCF or BCF depending on dialysis status
(pre-D RCF 31.4% (n = 188); pre-D BCF 22.4% (n = 165); HD RCF 29.3% (n = 99); HD BCF 25.9% (n = 116); p = 0.34).
There was no difference in mean eGFR between those patients with early AVF failure and those without
(11.2+/-0.2 ml/min/1.73 m2 vs. 11.6+/-0.4 ml/min/1.73 m2; p = 0.47). Uraemia was associated with early AVF
failure (serum urea: 35.0+/-0.7 mg/dl vs. 26.6+/-0.3 mg/dl (p < 0.001)).
Conclusions: We present the first in vivo evidence of an association between adverse early AVF outcomes
and uraemia. This is supported mechanistically by in vitro work demonstrating a pro-mitogenic effect of
hyperuraemic serum. We hypothesise that uraemia-driven upregulation of VSM cell proliferation at the site
of surgical insult in contributes to higher early AVF failure rates.
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Arteriovenous fistulae (AVF) are the dialysis access mo-
dality of choice for patients with end stage renal disease
(ESRD) [1,2]. They are associated with a six-fold reduc-
tion in the risk of systemic sepsis [3] and lower all cause
and cardiovascular mortality than tunnelled central ven-
ous catheters (TCVCs) [4,5]. For this reason both the
UK Renal Association and the Fistula First Initiative in
the United States have set targets that two-thirds of inci-
dent haemodialysis (HD) patients should commence dia-
lysis via an AVF [5,6].
There is little evidence however regarding the opti-
mal timing of vascular access creation in incident HD* Correspondence: EmmaAitken@nhs.net
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unless otherwise stated.patients. Broad consensus exists that timely surgical refer-
ral for access creation is important, however clinical prac-
tice guidelines are largely opinion-based and vary widely.
Furthermore, the exact timing of dialysis initiation for an
individual patient can be unpredictable [7]. The UK Renal
Association advocates that referral for vascular access
should occur when the patient enters CKD stage 4 taking
into account co-morbidities, rate of decline in renal func-
tion and the surgical pathway [5]. Similarly, the Canadian
Society of Nephrology guidelines recommend that a pa-
tient be referred with “creatinine clearance 15-20 ml/min
or serum creatinine 3.4-5.6 mg/dl (300-500 μmol/l)
depending on the size and weight of the patient” [8].
In contrast, the 2006 Kidney Disease Outcomes Quality
Initiative (KDOQI) guidelines provide a timeframe forLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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for dialysis” [9].
One of the major problems in vascular access planning
is the unpredictability of successful maturation. Initial
patency rates vary from 60-80% [10,11] and one recent
multicentre study found that 60% of AVFs were not suit-
able for cannulation 4-5 months after creation [12]. Vari-
ous risk factors for early AVF failure have been identified
including advancing age [13], female gender [14] and dia-
betes [15].
Several authors have speculated that the timing of ac-
cess creation itself may influence AVF outcome. Data
from the Dialysis Outcomes and Practice Patterns Study
(DOPPS) indicates that patients are less likely to start
HD via an AVF if there was a longer time from referral to
surgical evaluation or longer time from creation to first
cannulation [16]. The presence of a central venous cath-
eter at the time of commencing dialysis has also been
shown to be associated with poor AVF maturation [17].
Similarly, Weber and colleagues demonstrated a trend to-
wards improved patency in AVF created when the patient
was pre-dialysis, but the study was underpowered to for-
mally assess this secondary outcome measure [18].
Associations between the uraemia which occurs in
chronic kidney disease (CKD), altered immune response
[19] and deranged vascular biology [20,21] are well recog-
nised. It may be, therefore, that the uraemic state of
patients with ESRD influences AVF outcomes. In a rat
model of AVF maturation, Langer and colleagues found
inferior vessel dilatation and an exacerbation of neointi-
mal hyperplasia in uraemic animals [22]. These factors
may need to be taken into account when planning and
timing AVF creation.
The aim of this study was to evaluate the hypothesis
that uraemia drives vascular smooth muscle (VSM) cell
proliferation and impairs AVF maturation. In-vitro stud-
ies using VSM cells exposed to serum sampled from
subjects prior to a dialysis session (pre-HD) and after a
dialysis session (post-HD) were undertaken to quantify
the direct effect of hyperuraemic serum on cell growth.
Early fistula failure rates (6 weeks) were then compared
between pre-dialysis patients and those already on haemo-
dialysis for different eGFR and serum urea at time of AVF
creation and (in those patients who had already com-
menced HD) between patients who dialysed on the same
day as surgery and those who dialysed on the day prior
to surgery.
Methods
Approval was obtained from the West of Scotland
Research Ethics Committee. Research was conducted in
accordance with the Declaration of Helsinki. All sub-
jects providing blood samples provided written informed
consent.In vivo clinical study
Retrospective analysis of a prospectively collected data-
base of all simple arteriovenous fistulae created in our ter-
tiary referral vascular access centre during a three-year
period (January 2010-December 2012) was performed.
Patients were excluded if they were switching from
peritoneal dialysis to HD or if they had a failing trans-
plant. Patients undergoing brachiobasilic AVF creation
were also excluded, so the study population only included
brachiocephalic (BCF) and radiocephalic (RCF) fistulae.
Any patient who lost their AVF within six weeks for rea-
sons other than thrombosis i.e. ligation for steal or bleed-
ing was also excluded.
Demographic details (age, sex, number of previous fis-
tulae), operative details (site of AVF, type of anaesthetic)
and details regarding dialysis status and renal function
(dialysis modality, estimated glomerular filtration rate
(eGFR) and serum urea in patients who were pre-dialysis
(Pre-D) at the time of AVF creation and whether or not
the patient had pre-operative haemodialysis on the day
of surgery in patients who were already dialysis depend-
ant (HD)) were recorded. Serum urea and eGFR results
were obtained within 2 weeks prior to surgery. eGFR was
calculated using the Modification of Diet in Renal Disease
4-variable (MDRD-4) formula.
The primary outcome variable was clinical patency
at 6 weeks. Clinical patency was defined as an AVF
with thrill and bruit and adequate maturation to permit
needle cannulation if required as assessed by Vascular
Access Specialist Nurses. Secondary outcomes were func-
tional patency (defined as the ability of the AVF to
sustain six consecutive dialysis sessions with two nee-
dles in those patients who required haemodialysis),
clinical patency at time of hospital discharge (defined
as the presence of thrill or bruit) and date of loss of
clinical patency.
Statistical analysis was performed using the Statistical
Package for Social Sciences (SPSS) version 19.0 (SPSS,
Chicago, IL). Patients were stratified according to site of
AVF. Dialysis status (HD or pre-D), eGFR, serum urea
and whether or not the patient dialysed pre-operatively
were evaluated to determine if they affected early AVF fail-
ure. Normality of continuous variables was assessed using
the Shapiro-Wilk test and normal distribution confirmed.
Results are presented as a mean ± SEM or percentage
of the total population. Continuous data were compared
using a Mann Whitney U-test and categorical data
compared using chi-squared test. Risk factors for AVF
failure were evaluated using logistic regression ana-
lysis. Linearity, normal distribution and constant vari-
ance of residuals were confirmed to demonstrate no
significant interaction or relationship between vari-
ables. Variables that were not statistically significant
were removed for the model sequentially until the
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confidence intervals are presented. Only patients who
had complete demographic details available were con-
sidered for multivariate analysis. Kaplan Meier survival
curves were used to assess long-term patency of both RCF
and BCF. These were compared using a log-rank method.
p < 0.05 is considered significant.
In vitro study
Western blotting
Immunoblotting was undertaken as previously described
[23]. VSM cells isolated from a section of long saphenous
vein were seeded into six well multi plates and grown to
~80% confluence. The medium was then replaced with 0.1%
serum for 36 hours. Hyperuraemic pre-dialysis (pre-HD) or
less uraemic post-dialysis (post-HD) serum (15% v/v) was
added for 15 minutes to stimulate mitogenic signalling
pathways. Cells were homogenised in cell lysis buffer and
total protein was measured using Bio-Rad protein assay
from a 10 μl aliquot of the homogenate (absorbance mea-
sured at 595 nm). Samples were then diluted to a total
protein content of 1 μg/μl. A total of 20 μg of protein
was added to each lane for electrophoresis and trans-
ferred to a nitrocellulose membrane (Bio-Rad, Protean 2
system). Immunoblotting was undertaken using anti-
bodies for total ERK and phosphorylated ERK (Santa
Cruiz Biotechnology; sc-292838, sc-7976). After incuba-
tion with appropriate secondary antibodies, blots were
incubated in enhanced chemiluminescence reagents
(Amersham, UK) and exposed to photographic film
(Kodak X-OmatLS) to detect protein expression. The re-
active bands were analysed quantitatively by optical densi-
tometry using a GS-800 imaging densitometer (Bio-Rad),
and the amount phosphorylated ERK expressed as a ratio
of total ERK.
Cell proliferation: 3H thymidine assay
Cell proliferation was determined using serum-induced
[3H] thymidine incorporation as described previously
[23]. Briefly, VSM cells were seeded at 20,000 cells/wellTable 1 Patient demographics
Total population Patent at 6 w
Age (years) 60.5 ± 0.9 53.3 ± 2.2
Sex (% age male) 56.2% (n = 320) 58.3% (n = 241
Previous attempted AVF? 31.8% (n = 181) 20.5% (n = 85)
Anaesthesia
Local 24.1% (n = 137) 16.7% (n = 69)
Regional 50.3% (n = 286) 58.1% (n = 240
General 25.7% (n = 146) 25.2% (n = 104
Results are presented as mean ± SEM or percentage of total for the entire populatio
6 week patency. P-values compare patent vs not patent populations.into a 24 well plate. Cells were then quiesced for 48 hours
in media containing 0.1% (v/v) serum. The quiesced cells
were stimulated with serum for 24 hours with the
addition of 1 μCi/well of 3H thymidine (Amersham, UK)
for the final 6 hours. Thereafter cells were washed three
times for 10 minutes with ice cold phosphate buffered
saline containing 10% trichloroacetic acid, and finally
the contents of each well solubilised with 200 μls lauryl
sulphate (10%) plus sodium hydroxide (0.2 M). The solu-
bilised contents of each well were then transferred to scin-
tillant tube containing 2 mls scintillation fluid. Thereafter
radioactivity was quantified by liquid scintillation counting
of DPM (disintegrations per minute).
Results
In vivo clinical study
A total of 705 AVF were created during the three-year
period. 12 (1.7%) were excluded as the patient had a fail-
ing transplant and 23 (3.3%) were excluded as the pa-
tient was on peritoneal dialysis at the time of AVF
creation. 102 patients undergoing BBF formation were
also excluded, leaving 569 AVF for analysis (287 RCF,
282 BCF). Of these, 216 (38.0%) were created in patients
already on haemodialysis and 353 (62.0%) were created
in pre-D patients. Complete data was available in 700
patients. Missing data points related to demographic
data and were excluded from analysis. Table 1 outlines
the patient demographics and operative details.
There was no significant difference in the primary out-
come (loss of clinical patency at 6 weeks) of either RCF
or BCF depending on dialysis status (pre-D RCF 31.4%
(n = 188) vs. HD RCF 29.3% (n = 99), p = 0.34; pre-D
BCF 22.4% (n = 165) vs. HD BCF 25.9% (n = 116), p = 0.43)
(Table 2). There was no significant difference in either
patency on discharge or functional patency between pre-D
and HD groups (Table 2).
There was no difference in mean eGFR between
those patients with early AVF failure (loss of clinical pa-
tency at 6 weeks) and those without (11.2+/-0.2 ml/min/
1.73 m2 vs. 11.6+/-0.4 ml/min/1.73 m2; p = 0.47) (Table 3).eeks (n = 413) Not patent at 6 weeks (n = 156) p-value
64.1 ± 2.4 <0.01
) 50.6% (n = 79) <0.05
61.5% (n = 96) <0.001
<0.001
43.5% (n = 68)
) 29.5% (n = 46)
) 26.9% (n = 42)
n and in patients with achieving AVF patency at 6 weeks and not achieving
Table 2 Early patency for Pre-D and HD patients
Radiocephalic p-value Brachiocephalic p-value
Pre-D HD Pre-D HD
Primary outcome 0.43
Clinical patency at 6 weeks 69.6% (n = 130) 71.7% (n = 71) 0.34 77.6% (n = 128) 74.1% (n = 86)
Secondary outcomes 0.72
Patency on discharge 90.4% (n = 170) 91.9% (n = 91) 0.76 89.1% (n = 147) 90.5% (n = 105)
Functional patency* 80.3% (n = 98) 80.2% (n = 65) 0.87 84.1% (n = 122) 81.7% (n = 85) 0.79
Comparison of AVF outcomes of RCF and BCF created in patients who were pre-HD and those on HD at the time of AVF creation. *Functional patency is the ability
of an AVF to sustain HD for 6 consecutive sessions with two needles at any time during the follow-up period. AVF which failed to achieve initial patency on discharge
and AVF which never required needling (i.e. the patient remained pre-D or was transplanted prior to ever using the AVF) were excluded from this analysis.
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tency at 6 weeks. Mean serum urea in pre-D patients with
early AVF failure was 35.0+/-0.7 mg/dl compared to
26.6+/-0.3 mg/dl in those with patent AVF at 6 weeks
(p < 0.001). Similarly, in patients already established on
HD, loss of clinical patency at 6 weeks was more likely to
occur in patients who dialysed the day prior to surgery for
AVF creation compared to those who dialysed on the
same day as AVF creation (32.9% vs. 17.7%; p = 0.005)
(Table 3). The logistic regression model is shown in
Table 4. Uraemia, age, sex and site of AVF were independ-
ently associated with AVF patency at 6 weeks. eGFR was
removed from the model as there was an relationship with
uraemia and dialysis status removed as there was no sta-
tistically significant relationship.
Long-term clinical patency of RCF was better in patients
with lower serum urea when the AVF was created (p = 0.01;
Figure 1B). This association between uraemia and AVF
failure was not seen in BCF (p = 0.78; Figure 1D). Simi-
larly there was no association between eGFR and long
term RCF (p = 0.38; Figure 1A) and BCF (p = 0.61;
Figure 1C) patency.
In vitro study
Human VSM cells demonstrated increased capacity to
proliferate when stimulated with hyperuraemic serum ob-
tained immediately prior to haemodialysis (pre-HD) when
compared with cells stimulated with serum following dia-
lysis (post-HD) (Figure 2). Both the sensitivity to serum
and the maximum stimulatory response was significantlyTable 3 The effect of eGFR, uraemia, and pre-operative haem
Clinical patency at
eGFR (ml/min/1.73 m2)* 11.6 ± 0.4
Serum urea (mg/dl)* 26.6 ± 0.3
Pre-operative HD**
Percentage of patients having pre-operative HD 82.3%
Percentage of patients not having pre-operative HD 67.1%
Effect of eGFR, uraemia, and pre-operative haemodialysis on early AVF failure (loss o
who are pre-D; **For patients who are already dialysis dependant at time of AVF creatincreased in the pre-dialysis serum when compared to the
post-dialysis serum. The maximum stimulatory growth re-
sponse of VSM cells to 15% pre-dialysis serum was 1.47 ±
0.2 times that of the post-dialysis serum (p < 0.05). Figure 3
demonstrates the effect of 15% serum on stimulation of
the mitogenic ERK 1/2 VSM cell signalling pathway. Pre-
dialysis hyperuraemic serum significantly increased phos-
phorylation of ERK 1/2 in VSM cells when compared with
post-dialysis serum by a factor of 1.37 ± 0.1 (p < 0.05).
Discussion
We report the outcomes of a prospective, single-centre
observational study comparing early AVF failure rates in
patients who were pre-dialysis (pre-D) at the time of
AVF creation and those already on haemodialysis (HD).
Uniquely, these results are supported by basic science work
from our own group, providing mechanistic explanation
and validity for the results observed.
We found no difference in the primary outcome, pa-
tency at 6 weeks, between pre-D and HD patients for ei-
ther BCF or RCF. This novel finding is in conflict with
the results of Rayner and colleagues, who concluded that
dialysis via a TCVC at the time of access creation was
associated with early access failure [24]. Similarly, Weber
and colleagues achieved excellent “real world” outcomes
in their cohort of patients who had AVF created prior to
starting HD compared their cohort of patients who had
AVF creation delayed until after commencing HD, with
81% vs. 44% of patients using an AVF at 6 months [18].
It should be noted however that the criteria for referral forodialysis on early AVF patency
6 weeks Failure to achieve clinical patency at 6 weeks p-value
11.2 ± 0.2 0.47
35.0 ± 0.7 <0.001
0.005
17.7%
32.9%
f clinical patency at 6 weeks). Results are presented as mean+/-SEM *For patients
ion.
Table 4 Logistic regression analysis for factors associated
with early AVF failure
Coefficient Estimate Odds ratio 95% CI p-value
Intercept 60.5
Age (adjusted) 0.67 1.21 1.12,1.33 <0.01
Sex 0.65 1.32 1.06,1.58 <0.01
Site of AVF 0.06 2.40 1.25, 3.55 <0.001
Serum urea 0.04 1.6 1.06,2.14 <0.05
Logistic regression analysis evaluating risk factors for early AVF failure. Age,
sex, site of AVF and serum urea (OR 1.6) were found to be independently
predictive of AVF failure at 6 weeks.
Figure 1 Kaplan Meier survival curves comparing long term AVF clinic
1.73 m2; >15 ml/min/1.73 m2) and serum urea (<30 mg/dl; 30-40 mg/
creation. A. There was no difference in long-term RCF patency with differe
with lower serum urea at the time of AVF creation (p = 0.01). C. There was
D. There was no difference in long-term BCF patency depending on serum
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whilst the mean eGFR at time of AVF creation in our
study was 11 ml/min.
This is the first clinical study to evaluate the relation-
ship between renal function and AVF outcome. We
found no association between eGFR at the time of access
creation and either short or long-term patency. However
increasing serum urea was associated with worse clinical
patency at 6 weeks and poorer long-term outcomes from
RCF. Similarly, in those patients who had already com-
menced HD at the time of access creation, dialysis on
the same day as surgery was associated with better early
patency rates. These findings are consistent with our cellal patency stratified by eGFR (<10 ml/min/1.73 m2; 10-15 ml/min/
dl; >40 mg/dl) in patients who were pre-D at the time of AVF
nt eGFR (p = 0.38). B. Long-term patency of RCF was better in patients
no difference in long-term BCF patency with different eGFR (p = 0.61).
urea at time of AVF creation (p = 0.79).
Figure 2 The effect of human serum pre and post-dialysis on
VSM cell proliferation. *p < 0.05 one way ANOVA for repeated
measures, post dialysis serum vs. pre dialysis serum, n = 6 for each.
Figure 3 The effect of 15% human serum pre and post-dialysis
on phosphorylation of ERK 1/2 in VSM cells. *p < 0.05 unpaired,
two tailed t-test, post dialysis serum vs. pre dialysis serum, n = 5 for
each. Insert below shows two examples of blots where pERK 1/2 are
measured following stimulation with 15% serum taken either pre or
post dialysis.
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cell proliferation and neointimal hyperplasia which occur
at the site of endothelial injury and surgical trauma when
the AVF is created are exacerbated by the pro-mitogenic
effect of uraemic serum and are deleterious to early fistula
maturation.
The factors affecting AVF maturation are multifactor-
ial including vascular anatomy [25] and haemodynamics
[26,27], vessel quality [28] and immune and biochemical
properties [20,21]. Fistulae require adequate arterial in-
flow and venous outflow to permit maturation. Inflow
may be compromised by technical failure at the anasto-
mosis or a poor quality arterial tree. Outflow may be
impaired by anatomical or technical “kinking” of the ves-
sels or altered vascular biology leading to VSM cell prolifer-
ation, neointimal hyperplasia and venous outflow stenosis.
Uraemia alters vascular biology, physiology and biochem-
istry [19-21] and may contribute to both inflow and out-
flow difficulties.
Both arterial stiffness and vascular calcification are
increased in uraemic patients. In particular, calcification
of the media is unique to ESRD and may impair AVF mat-
uration by limiting arterial inflow [29]. Atherosclerosis is
accelerated in patients with chronic kidney disease (CKD)
with increased cardiovascular mortality [30] and increasedintima-medial thickness in both coronary and carotid ar-
teries [31,32]. An increased intima-medial thickness is
seen in the radial artery of uraemic patients and is associ-
ated with poor arterial inflow and failure of maturation in
RCF [33]. Most studies of CKD-mediated vasculopathy
focus on the arterial system, however it’s likely that the
detrimental effects of uraemia also affect the venous sys-
tem in a similar manner [34]. Arterial calcification is well
known to impair an artery’s ability to distend upon high
flow stimulation [35]. Lee and colleagues have recently
demonstrated extensive calcification within the intima and
media of venous segments harvested at the time of vascu-
lar access surgery which, similar to in the arterial setting,
may result in reduced venous compliance and inhibition
of the outward remodelling of the venous outflow re-
quired for AVF maturation [34,36].
VSM cell proliferation and neointimal hyperplasia occur
at the sites of vessel injury, for example the surgical anas-
tomosis, leading to perianastomotic stenosis [37]. Uraemia
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plasia, inhibit vascular repair and promote stenosis in a
rodent fistula model [22]. Additionally endothelial pro-
genitor cells (EPCs), which contribute to vessel repair and
neovascularisation, have reduced ability to migrate in ur-
aemic serum [38]. In the present study we have, for the
first time, isolated human VSM cells and exposed them
to hyperuraemic serum and compared proliferation and
the associated pro-mitogenic signalling. Our observations
support the notion that hyperuraemic serum contains
pro-growth factors which upregulate VSM cell prolifera-
tion and neointimal hyperplasia leading to early AVF fail-
ure. This process may occur de novo at the site of surgical
injury or may be an exacerbation of existing neointimal
hyperplasia of the outflow vein, which is known to predate
AVF creation in patients with CKD [39]. The clinical con-
sequences are likely to be most marked in small vessels, as
evidenced by the poorer long-term outcomes of RCF and
not BCF created in uraemic patients.
As with many in ESRD, our study is limited by a
heterogenous patient population. Multiple potential con-
founding variables exist. In particular, our assertion that
the improved AVF outcomes in patients who dialyse on
the same day as AVF creation reflects reduction in serum
urea may be erroneous. There are many potential con-
founding variables, including the administration of
systemic heparin and optimisation of cardiovascular func-
tion, which could improve AVF outcomes in patients hav-
ing HD on the same day as surgery. Secondly, our primary
endpoint of clinical patency at six weeks is vulnerable to
observer bias with different clinicians interpreting patency
differently. We chose this pragmatic endpoint which does
not include cannulation in an attempt to permit compari-
son between pre-D and HD patients. By using experienced
Vascular Access Nurse Specialists to assess patency we
have attempted to maintain standardisation and perform a
clinically relevant assessment of outcome.
Our results indicate the uraemia (independent of dia-
lysis status or eGFR) is a risk factor for early AVF failure.
This has significant clinical implications regarding the
timing of referral for AVF creation. Whilst most authors
favour early referral [8,40], a recent sensitivity analysis ac-
tually suggests comparable life expectancy and improved
quality of life for patients with CKD stage 4 when a watch-
ful waiting approach to access creation is adopted [41].
We would support creation of AVF in all incident patients
prior to starting HD. Our results indicate that, in order to
optimise maturation rates, even earlier referral prior to de-
velopment of significant uraemic symptoms may be re-
quired. Secondly, for a number of years it had been local
practice to expedite access creation in patients with rap-
idly declining renal function and progression to end-stage
disease. The results of this study have prompted a change
in that practice, given the poor AVF outcomes in uraemicpatients. It may be that there is a subset of patients who
are imminently requiring haemodialysis who would bene-
fit for commencement of HD via a TCVC, physiological
and biochemical optimisation and then AVF creation. Fi-
nally, the beneficial effect of same day haemodialysis has
significant service provision and logistical implications if it
is to be implemented for every patient.
Conclusions
This is the first clinical study to supporting our own
and previously published in vitro and animal models
demonstrating the deleterious effects of uraemia on AVF
maturation. These findings have clinical implications re-
garding access planning and optimal timing of referral for
vascular access.
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